Who founded Inmune Bio?

Inmune Bio was founded by Mark Lowdell, David Moss, Raymond Tesi in 2015.

How much funding has Inmune Bio raised?

Inmune Bio has disclosed $8M raised across 2 rounds.

Where is Inmune Bio headquartered?

Inmune Bio is headquartered in La Jolla, US.

Inmune Bio

NASDAQ: INMB

La Jolla, US · Founded 2015 · Nevada corporation

inmunebio.com ↗

INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.

BiotechDigital HealthHealthtech

Founders & leadership

Inmune Bio was founded in 2015 by Mark Lowdell, David Moss, and Raymond Tesi.

Mark LowdellCSO/CMO

David MossChief Financial Officer

Raymond TesiChief Executive Officer

J. Kelly GanjeiNamed on SEC filing

Terry R. KnappNamed on SEC filing

David J. MossCEO

Reported raises · per SEC filings

Form D private placements

$8M disclosed across 2 rounds · 2017–2019

▶$4.7MraisedMay 2019 · 5 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Raymond J. TesiExecutive Officer, Director
David MossExecutive Officer
Mark LowdellExecutive Officer
J. Kelly GanjeiDirector
Timothy SchroederDirector
David SzymkowskiDirector
Scott JudaDirector

Offering amount: $4.7M
Amount sold: $4.7M
First sale: Apr 2019
Incorporated: Corporation, Nevada, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$3.3MraisedJul 2017 · 29 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Mark LowdellExecutive Officer, Director
J. Kelly GanjeiDirector
David J. MossExecutive Officer, Director
Raymond TesiExecutive Officer, Director
Terry R. KnappDirector

Offering amount: $5M
Amount sold: $3.3M
Minimum investment: $10K
Sales commissions: $47.5K
Placement agents: Westpark Capital, Inc.
First sale: Mar 2017
Incorporated: Corporation, Nevada, 2015
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 6

by search overlap

Inimmune55 shared keywordsInimmune is a clinical-stage biotech company that discovers and develops immunotherapies based on innate immune modulation, including Toll-like receptor agonists, to treat inflammatory conditions such as allergy, cancer, and autoimmune disease. Its lead program, INI-2004, is an intranasal TLR4 agonist in Phase 2 trials for allergic rhinitis, alongside INI-4001, a TLR7/8 agonist in Phase 1 oncology trials, plus pre-clinical vaccine adjuvant work.

Immunome30 shared keywordsImmunome is a clinical-stage oncology company that discovers and develops targeted cancer therapies, with a focus on antibody-drug conjugates (ADCs). Its pipeline includes varegacestat (a gamma secretase inhibitor for desmoid tumors), IM-1021 (a ROR1-targeted ADC), and IM-3050 (a FAP-targeted radioligand), aimed at addressing high unmet need in cancer treatment.

Seeking Alpha29 shared keywordsSeeking Alpha is a financial research platform that provides stock analysis, investment tools, and market coverage across asset classes to investors. The platform aggregates research from thousands of analysts and investors, offering ratings, articles, and investment ideas.

Immuneering29 shared keywordsImmuneering develops Deep Cyclic Inhibitors, a class of oncology medicines designed to pulse dosing faster than cancer's adaptive mechanisms to limit resistance and reduce side effects. The company targets more durable tumor control and improved tolerability for cancer patients.

Immunai28 shared keywordsImmunai develops AMICA, a data platform for decoding the immune system to accelerate drug discovery and development. The company serves pharmaceutical and biotech researchers working on inflammatory and oncological therapies.

Infinimmune28 shared keywordsInfinimmune discovers and develops antibody therapeutics using proprietary sequencing technology and AI-powered optimization. The company serves pharmaceutical and biotech partners developing treatments across 350+ disease targets.

Companies competing with Inmune Bio for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 1 SBIR/STTR award

Federal grants — no equity taken

Agency	Phase	Year	Amount
National Institutes of Health (NIH)National Institutes of Health	Phase II	2020	$2M

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

Frequently asked questions

What does Inmune Bio do?: INmune Bio is a clinical-stage biotechnology company developing immunotherapies, including XPro1595, aimed at treating neurodegenerative and psychiatric diseases through a biomarker-directed approach. The company works on translating inflammatory therapies into clinical treatments for neurologic and other diseases.
Who founded Inmune Bio?: Inmune Bio was founded by Mark Lowdell, David Moss, Raymond Tesi in 2015.
How much funding has Inmune Bio raised?: Inmune Bio has disclosed $8M raised across 2 rounds.
Where is Inmune Bio headquartered?: Inmune Bio is headquartered in La Jolla, US.